This is a preview of subscription content, log in via an institution to check access.
References
Kaplan JL, Marx JA. Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study. Ann Emerg Med 1993 Feb; 22: 187–90
Matzke GR, Alexander ACM, Frye RF, et al. The disposition of nalmefene is significantly altered in patients with end stage renal disease. Clin Pharmacol Ther 1995 Feb; 57: 218
Dixon R, Howes J, Gentile J, et al. Nalmefene: intravenous safety and kinetics of a new opioid antagonist. Clin Pharmacol Ther 1986 Jan; 39: 49–53
Clark WM, Coull B, Hendin B, et al. Randomized trial of Cervene, a kappa receptor selective opioid antagonist, in acute ischemic stroke. Neurology. 1995 Apr; 45 Suppl. 4: 241
Yum SW, Faden AI. Comparison of the neuroprotective effects of the N-methyl-D-aspartate antagonist MK-801 and the opiate- receptor antagonist nalmefene in experimental spinal cord ischemia. Arch Neurol 1990 Mar; 47: 277–81
Rights and permissions
About this article
Cite this article
Nalmefene. Drugs R&D 1, 32–33 (1999). https://doi.org/10.2165/00126839-199901010-00012
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199901010-00012